Teva (NYSE: TEVA) CFO converts restricted units into 248,756 shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. executive vice president and chief financial officer Eliyahu Sharon Kalif exercised restricted share units into ordinary shares on March 3, 2026.

He converted 49,800 and 141,478 restricted share units, resulting in 248,756 ordinary shares held directly as of that date.

Insider Trade Summary

191,278 shares exercised/converted

Mixed 4 txns

Insider Kalif Eliyahu Sharon

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	49,800	$0.00	--
Exercise	Restricted Share Units	141,478	$0.00	--
Exercise	Ordinary Shares	49,800	$0.00	--
Exercise	Ordinary Shares	141,478	$0.00	--

Holdings After Transaction: Restricted Share Units — 49,802 shares (Direct); Ordinary Shares — 107,278 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024, March 3, 2025 and March 4, 2026, and 49,802 vesting on March 3, 2027. Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalif Eliyahu Sharon

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		M		49,800	A	(2)	107,278	D
Ordinary Shares(1)	03/03/2026		M		141,478	A	(2)	248,756	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/03/2026		M			49,800	(3)	(3)	Ordinary Shares(1)	49,800	$0	49,802	D
Restricted Share Units	(2)	03/03/2026		M			141,478	(4)	(4)	Ordinary Shares(1)	141,478	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024, March 3, 2025 and March 4, 2026, and 49,802 vesting on March 3, 2027.

4. Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

	/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TEVA CFO Eliyahu Sharon Kalif report?

Eliyahu Sharon Kalif reported exercising 49,800 and 141,478 restricted share units into Teva ordinary shares on March 3, 2026, leaving him with 248,756 ordinary shares held directly after the transactions.

What types of securities were involved in the TEVA Form 4 filing?

The filing shows restricted share units being exercised and converted into Teva ordinary shares. The transactions are coded “M,” indicating exercise or conversion of derivative securities, all held under direct ownership by the reporting executive vice president and chief financial officer.

How many Teva shares did the CFO hold after the reported transactions?

After the March 3, 2026 exercises and conversions, Eliyahu Sharon Kalif directly held 248,756 ordinary shares of Teva Pharmaceutical Industries Ltd., according to the total shares following the final reported non-derivative transaction in the Form 4 filing.

What do Teva’s restricted share units represent in this Form 4?

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share, as disclosed in the footnotes to the Form 4 filing.

How were Teva’s restricted share units granted and vested for the CFO?

One grant of restricted share units was made on March 3, 2023, vesting in several annual tranches, and another set was earned on January 27, 2026 after performance criteria were certified, then vested on March 3, 2026 after time-based vesting conditions were met.

Can Teva ordinary shares be held as American Depositary Shares (ADS)?

Yes. The filing states Teva ordinary shares may be represented by American Depositary Shares, with each American Depositary Share currently representing one ordinary share, providing an alternative way for investors to hold an interest in Teva equity.